Movers September
17-Aug-16
Mike Hannay is the new managing director of the East Midlands Academic Health Science Network (EMAHSN). He will play a key role at the heart of the East Midlands' healthcare system, working with partners across health, academic, social care, industry and third sectors to build collaboration and spread health innovation at pace and scale. Mike has joined EMAHSN from ThermoFisher Scientific, where he was vice-president for the UK BioPharma Services division, a role that built upon his significant experience both nationally and internationally, including vice-president of medicines development at AstraZeneca.
Healthcare services provider Celesio UK has appointed Ruth Poole as its new speciality director. This new role also holds a position on the Celesio UK country board. As speciality director, Ruth will lead Celesio UK's work with third parties to meet patients' needs. She will direct work with strategic pharma, healthcare and product manufacturing partners to influence the way patients behave, improve the patient experience and to support the NHS outcomes framework. Ruth joins from Healthcare at Home, where she held the position of group commercial director.
Global CRO Smithers Viscient has appointed Dr Steve Dean as managing director. Steve is a highly experienced business and science leader with over 25 years spent within CROs including WIL Research and Harlan Laboratories. His strengths lie in strategic planning, operational management and people leadership. Steve will assume operational responsibility for the Smithers Viscient European site in Harrogate, UK.
Chronos Therapeutics has appointed Fraser Murray (right) and Timothy Schulz-Utermoehl as vice-presidents of preclinical development. Fraser and Timothy join Chronos from Polleo Pharma, a UK biotech start-up company they co-founded. Both have substantial scientific management expertise acquired in large pharmaceutical companies and previously held senior positions at Shire, AstraZeneca and Merck. Fraser was senior director and head of discovery biology for Shire Speciality Pharmaceuticals, focused on CNS and GI disorders, and Timothy was a director within the exploratory projects department for Shire Speciality Pharmaceuticals in the UK. They will be responsible for three preclinical research programmes recently acquired by Chronos.
CRO ClinTec International has appointed Alastair MacDonald as global head of clinical operations. Alastair joins from AstraZeneca with almost 25 years' experience in clinical development, most recently as global medical evidence and observational research director. At AZ he made key contributions to the development pipeline and commercialisation, with a focus on oncology, and within other key strategic areas including cardiovascular, metabolic and respiratory medicine. His significant oncology background includes recent contributions to the development and subsequent commercialisation of a number of key treatments across a broad range of cancer diseases.
Professor Sir Jonathan Abridge has been appointed as Healthcare at Homes's new clinical director. Jonathan joined Healthcare at Home as director of quality and governance in 2013, following the company's acquisition of home care provider MediHome. With a long and distinguished career within UK healthcare, he has particular expertise in health system organisation, accreditation, governance and regulation. Jonathan is a former chief nurse of the Oxford University and Cambridge University Teaching Hospitals. He is also former chief nurse and interim chief executive of Barts and the London NHS Trust, as well as the former inaugural president of the UK Nursing and Midwifery Council.
Life has appointed Sophie Gibbs as senior account manager. Sophie has over 10 years of healthcare agency experienc and has worked on a wide range of therapy areas, such as epilepsy, oncology and COPD. She has previously worked at Pan, LEC and Lime on a variety of UK and global accounts, delivering materials across a number of different channels to various stakeholders. Her key responsibilities at Life will be to deliver excellence on her accounts from service, though to final delivery and beyond.
PAREXEL has appointed four executives to its senior leadership team, the business review committee: Michelle Graham, senior VP and chief human resources officer; Joshua Schultz (pictured), senior VP and worldwide head of PAREXEL Access; David Godwin, senior VP of global business development; and Sy Pretorius, senior VP and chief scientific officer. Michelle joined the company in 2015 and is responsible for the design and launch of its people strategy, talent agenda and refined human resources operating model. Joshua joined the company in 2005 and oversees the global late phase business. David joined PAREXEL in 1989 and is responsible for the business development efforts for many of the company's services. Sy joined PAREXEL in 1996 and previously held leadership roles in various countries. He serves as chief scientific officer and works closely with clients to design and optimise drug and device development strategies as well as find, evaluate and purchase assets.
Virgo Health has expanded its Health Education division with the appointment of medical doctor Ajay Aggarwal. At Chelsea & Westminster Hospital Ajay worked in a number of specialties including acute medicine, gastroenterology and colorectal surgery. He also spent some time in dermatology and general practice. Throughout his student and clinical career, Ajay has been trying to identify more efficient ways to enhance patient care through empowering doctors. He developed a virtual clinic for patients with skin diseases to improve monitoring and follow-up in a cost-effective way. Recognising the need for doctors to lead the changes for improving care, he also chaired the member recruitment and student engagement workstream at the Faculty of Medical Leadership and Management.
Probiodrug has announced updates to its supervisory board and management team. Olivier Litzka, partner at Edmond de Rothschild Investment Partners (EdRIP) and member of the Supervisory Board of Probiodrug since October 2009, will step down from his Board position on September 12, 2016. Olivier joined the Supervisory Board when EdRIP invested into privately held Probiodrug for the first time. Meanwhile, chief business officer Mark Booth will leave Probiodrug for personal reasons. His responsibilities will be taken over by Konrad Glund, CEO of Probiodrug. Erich Platzer, chairman of the supervisory board: "We would like to thank Olivier for his valuable contribution to Probiodrug over the last seven years. His knowledge and support has played an important role in the growth and development of the company."